Current Gastroenterology Reports

, Volume 7, Issue 6, pp 485-491

First online:

Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis

  • Laurence J. EganAffiliated withDepartment of Pharmacology, National University of Ireland, Clinical Science Institute, University College Hospital
  • , William J. Sandborn

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Traditional medications for inflammatory bowel disease are small molecule drugs, most of which were developed for use in other diseases before being found to be efficacious for the treatment of ulcerative colitis or Crohn’s disease. Recently, several exciting alternative approaches to the medical treatment of inflammatory bowel disease have been developed. These include biologic, probiotic, and apheresis therapies that offer certain advantages over traditional drug therapy for inflammatory bowel disease. The purpose of this review is to assess the current state of knowledge about novel biologic, probiotic, and apheresis therapies and to analyze how best to incorporate these therapies into evolving management paradigms of inflammatory bowel disease.